The ENCHANT-1 trial (NCT01677455): An open label multicenter phase 2 proof of concept study evaluating first line ganetespib monotherapy in women with metastatic HER2 positive or triple negative obreast cancer (TNBC)
Authors: Awada, A., Spector, N., El-Hariry, I., Rodriguez, A.A., Erban, J.K., Cortes, J., Gomez, H., Kong, A., Hickish, T., Fein, L., Vahdat, L., MacPherson, I., Canon, J.-L., Mansoor, S., Giovanne, A., McAdam, K., Vukovic, V.M., Yalcin, I., Bradley, R., Proia, D., Mano, M.S., Perez, E.A., Cameron, D.A.
Journal: CANCER RESEARCH
Publication Date: 15/12/2013
Volume: 73
eISSN: 1538-7445
ISSN: 0008-5472
DOI: 10.1158/0008-5472.SABCS13-P2-16-23
Source: Web of Science